66. IgA nephropathy Clinical trials / Disease details
Clinical trials : 255 / Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05016323 (ClinicalTrials.gov) | September 9, 2021 | 17/8/2021 | A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. | A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Groups, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. | IgA Nephropathy | Drug: HR19042 Capsules;Drug: Placebo | Jiangsu HengRui Medicine Co., Ltd. | NULL | Recruiting | 18 Years | N/A | All | 210 | Phase 2 | China |
| 2 | NCT04887532 (ClinicalTrials.gov) | July 1, 2021 | 13/5/2021 | A Trial of HR19042 Capsule in Healthy Chinese Subjects | Safety and Pharmacokinetics of HR19042 Capsule After Single Administration in Healthy Chinese Subjects | Primary IgA Nephropathy | Drug: HR19042 capsule | Jiangsu HengRui Medicine Co., Ltd. | NULL | Completed | 18 Years | 45 Years | All | 12 | Phase 1 | China |